Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
Immunostart: Prephase Tafasitamab, Retifanlimab, and Rituximab (TRR), Followed by TRR With Standard Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
Sponsor: University of Washington
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Dose limiting toxicity rate
Time frame: From treatment start to end of cycle 3 (each cycle is 3 weeks)
Secondary Endpoints
Overall response rate
Progression-free survival
Overall survival
Eligibility Criteria
Inclusion Criteria: * Patients with previously untreated diffuse large B cell lymphoma or grade 3B follicular lymphoma (of any stage). Patients may have de novo DLBCL, and /or any of the following: * Composite lymphomas, which include both diffuse DLBCL and another histology (most commonly follicular lymphoma) in the same lymph node, * Transformed lymphoma with DLBCL histology, as long as the patient has not received prior therapy for lymphoma, * Discordant presentations, such as DLBCL in a lymph node and low-grade lymphoma such as follicular lymphoma in the bone marrow, and * High grade B-cell lymphoma (including "double hit" lymphomas or high grade B-cell lymphoma-not otherwise specified \[HGBCL-NOS\]) is permitted if the patient is not eligible for or declines intensive therapy * Be willing and able to provide written informed consent/assent for the trial * Be \>= 18 years of age on day of signing informed consent * Have measurable disease, including at least 1 nodal site …
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →